Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05386329 · ClinicalTrials.gov registry record · NA
Therapist-Guided Smartphone-Delivered CBT for MDD
A NA study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- NA
- Development phase
- 28
- Enrollment target
NCT05386329: Completed NA study, sponsored by Massachusetts General Hospital.
NCT05386329 is a NA study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 28 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05386329, a NA study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 28 participants
- Enrollment target
Study Summary
We are testing a smartphone app that provides therapy for depression. Participants will also receive short weekly virtual appointments with a therapist. Researchers want to know if this new treatment is usable, whether participants are satisfied with it, and whether it can help lower symptoms.
Primary Outcome
To determine feasibility, we will report rates of and reasons for participant dropout from the trial.
Interventions
- BEHAVIORAL Mindset: Therapist-guided smartphone-delivered CBT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2022-05-11 |
| Est. Completion | 2023-08-07 |
| Phase | NA |
What the finished NCT05386329 record still lists
NCT05386329 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which Mindset: Therapist-guided smartphone-delivered CBT is the first listed.
NCT05386329 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05386329 about?
NCT05386329 is a clinical study titled "Therapist-Guided Smartphone-Delivered CBT for MDD". We are testing a smartphone app that provides therapy for depression. Participants will also receive short weekly virtual appointments with a therapist. Researchers want to know if this new treatment is usable, whether participants are satisfied with it, and whether it can help lower symptoms.
What is the current status of trial NCT05386329?
This trial is currently completed. It is a NA study. The enrollment target is 28 participants. The study started on 2022-05-11. Estimated completion is 2023-08-07.
What interventions are being tested in trial NCT05386329?
The interventions under investigation include: Mindset: Therapist-guided smartphone-delivered CBT (BEHAVIORAL).
Who is sponsoring clinical trial NCT05386329?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05386329's enrollment target sits among peer trials
28 1704th of 2000 higher than 293 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI